“Similar” Biologics Could Use One Clinical Trial For All Indications – Teva

Abbreviated applications for "similar" follow-on biologics could include clinical data in one indication to support approval in all innovator indications, Teva Senior Director Global Clinical Research Yafit Stark, PhD, said